Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
Xenetic Biosciences Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)
Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position
Affimed Reports 2023 Financial Results and Operational Progress
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Affimed Announces 1-for-10 Reverse Stock Split
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.